Medicine guide

Exjade 250 mg

As listed in the register: Exjade 250 mg, dispergierbare Tabletten

250 mg ·

  • Prescription only
  • Everything that fits nowhere else, such as contrast media
Active substance
Deferasiroxum
Made by
Novartis Pharma Schweiz AG

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Behandlung der transfusionsbedingten Hämosiderose. Behandlung von chronischer Eisenüberladung, die eine Chelattherapie erfordert, bei Patienten mit nicht-transfusionsabhängiger Thalassämie ab 10 Jahren.

From the official label · 2026-09-30 · Swissmedic

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

BulgariaNo exact match for this strength and form

European UnionNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

Details

Made byNovartis Pharma Schweiz AG
Active substanceDeferasiroxum
Used inEverything that fits nowhere else, such as contrast media
Strength250 mg
ClassificationV03AC03 · Everything that fits nowhere else, such as contrast media
Dispensing (as stated by the register)Abgabekategorie B
Name in the registerExjade 250 mg, dispergierbare Tabletten
Packs28 Tablette(n) · 84 Tablette(n)
Zulassungsnummer57466
Dosisstärke2

Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician

Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.